Sequencing Efficacy Safety Dosing and Administration Expert Conversations Previous Next Read more Previous Play Next Real-world evidence: GIOTRIF® in Japan 17/04/2024 | Author: Boehringer Ingelheim Document ID: PC-MY-102093 Efficacy MYGIO2022COM||GIOTRIF® provides ≥3 years long-term response even with dose modification MYBIONEGIO2022||South Korean Dataset: Frontline Giotrif in Uncommon EGFR Mutations SEREAL||First-line GIOTRIF® data in over 30 real-world studies to-date GIOTRIF® safety and effectiveness in the real world Real-world evidence: GIOTRIF® in Japan MYSEREAL||Real-world evidence: GIOTRIF® in Taiwan Video: Uncommon EGFR pooled analysis in 693 patients Real-world evidence: GIOTRIF® in South Korea SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients MYGIO2022COM||GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC RWDRI||Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan RWDRI||Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan SEREAL||GIOTRIF® RWE in patients with brain metastases SEREAL||Impact of GIOTRIF® in delaying CNS progression SEREAL||GIOTRIF® RWE in Taiwan SEREAL||GIOTRIF® efficacy in the real-world SEREAL||GIOTRIF® in LUX-Lung 7 MYGIO2022COM||GIOTRIF® in elderly MYBIONEGIO2022||GIOTRIF® in uncommon EGFR mutations RWDRI||GIOTRIF® in Uncommon Mutation - A database analysis of >1000 NSCLC Patients RELATED CONTENT Read more PDF Real-world evidence: GIOTRIF® in South Korea Download Opens in new tab Read more PDF SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients Download Opens in new tab Read more PDF MYGIO2022COM||GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC Download Opens in new tab Read more 3:01 Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan Watch now Opens in new tab Read more 2:37 Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan Watch now Opens in new tab Read more PDF SEREAL||GIOTRIF® RWE in patients with brain metastases Download Opens in new tab Pagination Load more Home Oncology Giotrif Efficacy Real-world evidence: GIOTRIF® in Japan
Read more PDF SEREAL||GIOTRIF® Uncommon EGFR pooled analysis in 693 patients Download Opens in new tab
Read more PDF MYGIO2022COM||GIOTRIF® vs gefitinib for 1st-line treatment of EGFRm+ NSCLC Download Opens in new tab
Read more 3:01 Real-World Effectiveness of GIOTRIF® vs Osimertinib - Data from Japan Watch now Opens in new tab
Read more 2:37 Real-World Effectiveness of GIOTRIF® on Brain Metastases – Data from Korea and Taiwan Watch now Opens in new tab